The Strategic Advisory Group of Experts (SAGE) on immunization1 met on 12-14 April 2016 in Geneva, Switzerland.
Worldwide, dengue is the most extensively spread mosquito-borne viral illness. It is caused by 4 related viruses (DENV 1-4). In the last 60 years, the incidence of clinical dengue cases reported to WHO has increased 30-fold, with a greatly increased geographic range and expansion from urban to rural settings.
The objectives of the WHO Global Strategy for dengue prevention and control (2012-2020) are to reduce mortality and morbidity from dengue by 2020 by at least 50% and 25% respectively
The first dengue vaccine, CYD-TDV (Dengvaxia®), a live attenuated vaccine, has now been licensed by several dengue-endemic countries in Asia and Latin America for use in 9-45 or 9-60 year-olds, and is under regulatory review in several others.
The WHO Strategic Advisory Group of Experts (SAGE) on immunization has recommended that a vaccine for dengue, called Dengvaxia (CYD-TDV), be considered for use in geographic settings with high endemicity.
The WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYD-TDV in April 2016 and recommended countries consider introduction of the vaccine only in geographic settings (national or subnational) with high endemicity. A WHO vaccine position paper will be published outlining WHO recommendations in July 2016.
There are approximately five additional vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Additional technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies.
The growing global epidemic of dengue is of mounting concern, and a safe and effective vaccine is urgently needed. WHO expects vaccines to be an integrated part of the Global dengue prevention and control strategy (2012-2020).